CNV+ Breast Cancer NGS Panel
Breast Cancer
Key Facts
About NuProbe
NuProbe is a privately held, US-based company founded in 2016 with a mission to improve the analytical sensitivity of DNA biomarker detection for cancer research and diagnostics. Its core technology platform includes Blocker Displacement Amplification (BDA) for rare allele enrichment on PCR/digital PCR and Quantitative Amplicon Sequencing (QASeq) for highly multiplexed, UMI-based NGS assays. The company has secured a significant $50M funding round, entered a key licensing agreement with Bio-Rad, and operates with a dual business model of developing research-use assays and providing custom assay development services to biopharma. NuProbe is positioned to address the growing need for sensitive liquid biopsy and tissue-based testing in oncology.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Antifibrotic Therapy Program | MeCo Diagnostics | Pre-clinical |
| inPROBE for HER2 | SDS Optic | Clinical Investigation |
| ACT‑BC1 | Anthrocell | Preclinical |
| APA-1000 Breast Thermotherapy System | Medifocus | Phase III |
| Early‑Detection Breast Cancer Screening | Karkinos Healthcare | Market |
| Unnamed Breast Cancer Program | Click Therapeutics | Pilot/Phase 2 |
| Lerociclib (Lerocliclib) | Chemogenics BioPharma | Phase 3 |
| AT-017 | Asieris Pharmaceuticals | Not Specified |
| CDK2 inhibitor | Acellera | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Maveropepimut-S (MVP-S) | BioVaxys | Clinical Evaluation |
| Cannabics® BRST-33 | CNBX Pharmaceuticals | Discovery |